Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011849 (diabetes)
 277,896 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Fifty-nine patients with chronic pancreatitis were studied in retrospect. The incidence of overt diabetes was high, 36/59. Half of the diabetics were insulin-dependent, and among these labile diabetes with hyperglycemia and high amounts of glucose in the urine was not uncommon. Hypoglycemic episodes were noted in 14 of the 18 insulin-treated patients, and in 3 patients severe hypoglycemia was believed to be the cause of death. Mechanisms leading to such disastrous hypoglycemia are discussed, and a hypothesis regarding lack of glucagon as the cause of severe hypoglycemic attacks was experimentally tested by measuring pancreatic glucagon in plasma in two patients with pancreatic diabetes and severe brain damage following hypoglycemic coma. Low basal glucagon values were found, and the normal rise upon insulin-induced hypoglycemia was not seen. From these results it may be justified to suggest, firstly that glucagon should be used in the management of severe hypoglycemia in chronic pancreatitis, and secondly that a certain degree of hyperglycemia should be allowed in the treatment of diabetes in these patients.
 ...
PMID:Diabetes and hypoglycemia in chronic pancreatitis. 86 1

A retrospective analysis was performed on 70 patients with diabetes mellitus who required nutritional support over the 10-yr period 1979-1989. Information was available for 65 patients, of whom 55 had non-insulin-dependent diabetes mellitus (NIDDM). Enteral nutrition (EN, 750-2200 kcal/day) was given to 40 NIDDM patients (group A) and 6 insulin-dependent diabetic (IDDM) patients (group B), and parenteral nutrition (PN, 1600-2400 kcal/day) was given to 18 NIDDM patients (group C) and 4 IDDM patients (group D). Three NIDDM patients required both types of feeding. Preadmission diabetes treatment remained the same during feeding for 31% of the total group (38% of group A, 33% of group B, 23% of group C, and 0% of group D). The NIDDM patients in group C who received insulin during PN required a high daily dose of approximately 100 U. The IDDM patients on PN required an increase of 225% from their preadmission daily dose. The likelihood of a patient requiring a major change from preadmission diabetes therapy depended mainly on the severity of the underlying illness and on the type of feeding (greater with PN) but not on preadmission therapy, age of patient, or type of EN (cyclic vs. continuous). Hypoglycemic episodes were uncommon in all groups. There were no significant differences between the prefeeding and feeding blood glucose levels and HbA1c results.
 ...
PMID:Management of diabetic patients requiring nutritional support. 142 78

This multicenter study of patients with non-insulin-dependent diabetes mellitus (NIDDM) was undertaken (1) to determine the incidence of insulin antibody formation in such patients before exposure to exogenous insulin; (2) to assess the long-term immunologic response to semisynthetic human insulin (ssHI) in new insulin users and in patients transferred from animal insulin; and (3) to document the efficacy and safety of ssHI in both new and transfer patients. In addition, a substudy at one participating center was designed to compare the effects of a twice-daily versus a once-daily regimen in initiating ssHI therapy in new patients with uncontrolled NIDDM. Among the 37 new patients, only one had detectable insulin antibody levels before administration of insulin. After ssHI therapy was begun, this patient's antibody levels rapidly fell below the assay's limit of detection. Detectable levels of antibodies to human insulin were found in only 36% of 28 new patients after 12 months of therapy. As expected, the prevalence of insulin antibodies among animal-insulin users was high: 82% of the 17 transfer patients had detectable insulin antibody levels (mean, 2.27 mU/ml) at baseline. After six months of treatment with ssHI, antibody levels decreased significantly (mean, 0.75 mU/ml; P less than 0.05). Control of glycemia was assessed by measurement of glycosylated hemoglobin. Values decreased significantly (P less than 0.01) in the new patients after the introduction of ssHI and remained stable in the transfer group after initiation of ssHI therapy. Hypoglycemic episodes were infrequent in both groups. In initiating ssHI therapy in new patients hospitalized with uncontrolled NIDDM, a twice-daily regimen resulted in a more rapid normalization of glycemia and earlier discharge than did the standard once-daily regimen. In conclusion, the results of this study provide further evidence that NIDDM and insulin-dependent diabetes mellitus (IDDM) are immunologically different disorders, with the immune system probably not involved in the pathogenesis of NIDDM. The data also indicate that ssHI is less immunogenic than animal insulin and that it is effective and safe in the management of NIDDM both in first-time insulin users and in patients transferred from animal-species insulin. Thus ssHI would appear to be useful in treating NIDDM, especially in patients who require intermittent insulin therapy.
 ...
PMID:Insulin antibodies in non-insulin-dependent diabetes mellitus: effect of treatment with semisynthetic human insulin. 266 Sep 98

Sixty-one insulin-requiring non-insulin-dependent (type II) diabetic patients who had been transferred from a regimen of mixed intermediate and short-acting insulin to a fixed regimen of premixed insulin (70% neutral protamine Hagedorn and 30% regular, human semisynthetic insulin) given twice daily were studied retrospectively. The average age was 65 years (range, 35 to 84) and the average duration of their diabetes was 13.8 years (range, 1.5 to 33 years). Thirty-one percent were men, 69% women. Hemoglobin A1c (HbA1c) dropped significantly after transfer from a mean of 12.3% to a mean of 9.2% (P less than 0.001). After an average of 14.1 months, 40 patients still had a lower HbA1c (P less than 0.01), showing sustained improvement. The mean HbA1c at the last visit was 10.2% (normal range, 5.5% to 8.5%) with the average reduction in HbA1c being 2.1%. This sustained improvement occurred without a significant gain in weight (P = 0.63) or a significant increase in total insulin doses (median, 2 units), and was independent of the type of insulin used previously. Hypoglycemic episodes actually declined from an average of 1.0 to 0.6 per month. Of those patients who had previously not reported hypoglycemia, only 28% reported hypoglycemic events, and of those reporting previous hypoglycemia, 57% experienced a reduction. This surprising improvement in glycemic control was not due to compliance with insulin injections or remote premixing of insulin but possibly due to the increased accuracy of measuring the premixed insulin dose. The convenience and stability of a premixed insulin regimen results in better glycemic control in the insulin-requiring non-insulin-dependent diabetic population.
 ...
PMID:Efficacy of a premixed semisynthetic human insulin regimen. 269 22

Symptomatic hypoglycemia developed 5 to 45 months after transplantation in nine children who had renal transplants before 6 years of age. During hypoglycemia, serum glucose levels ranged from 14 to 39 mg/dl (0.8 to 2.1 mmol/L). Hypoglycemic episodes occurred between 1.7 and 7.5 years of age. Six patients had generalized seizures; the remaining three had diaphoresis with stupor or lethargy. None of the children had serious infections, diabetes, congenital defects of glucose metabolism, or a history of treatment with insulin or oral hypoglycemic agents. Six patients had hypoglycemic symptoms after a prolonged fast, and at least four had ketosis. Eight of the nine patients were receiving propranolol when hypoglycemia occurred. No differences in the daily prednisone dose, the number of transplant rejection episodes, or the frequency of treatment with medications other than propranolol were noted between hypoglycemic patients and 56 normoglycemic age-matched renal transplant recipients. All hypoglycemic patients were subsequently treated with frequent feedings and discontinuation of propranolol. No further hypoglycemic episodes have occurred in eight of nine patients. Symptomatic hypoglycemia should be recognized as a potentially devastating complication of pediatric renal transplantation.
 ...
PMID:Hypoglycemia in pediatric renal allograft recipients. 305 55

Hypoglycemic episodes occur commonly in patients with insulin-dependent (Type I) diabetes and are associated with several negative sequelae. These include unpleasant symptoms, deterioration in cognitive-motor functions, embarrassment, accidents, unconsciousness, seizures, and even death. Although hypoglycemic disruptions in cognitive and motor function caused by neuroglycopenia are well-documented, the effects of hypoglycemia on other areas of psychosocial function have received less scientific attention. This paper examines the impact of hypoglycemia on emotional status, social behavior, and relationships. The physical symptoms and cognitive impairment that occur with hypoglycemia are caused primarily by hormonal changes and neuroglycopenia. These physiologic responses also seem to cause negative changes in affect and social behavior. These include changes in acute mood state, such as feelings of tension and anger, as well as negative interpersonal behavior, such as argumentiveness. Patients may also develop significant fear of hypoglycemia (FOH) and engage in behaviors aimed at avoiding low blood glucose levels, which may jeopardize metabolic control. Nondiabetic family members, who witness episodes and often must provide emergency treatment, can experience significant distress. Parents of diabetic children who have experienced unconsciousness exhibit high FOH, as do spouses of diabetic adults who have frequent episodes. Taken together, the research clearly shows that hypoglycemia can have a significant negative impact on psychosocial function and quality of life, which has important clinical and empirical implications.
 ...
PMID:The Emotional, Social, and Behavioral Implications of Insulin-Induced Hypoglycemia. 1032 Apr 43

This article examines the relationship between hypoglycemia and brain function in children with type 1 diabetes. Hypoglycemic episodes occurring in the first 5 years of life may permanently disrupt cognitive function in a subset of children with diabetes, and a single acute episode of hypoglycemia may produce a transient reduction in mental efficiency, alter the electroencephalogram, and increase regional cerebral blood flow. Because iatrogenic development of hypoglycemic unawareness and autonomic failure are the most likely mediators of moderately severe hypoglycemia, medical management efforts should be directed at the prevention of frequently recurring, mild hypoglycemia.
 ...
PMID:Hypoglycemia in children with type 1 diabetes mellitus. Risk factors, cognitive function, and management. 1060 25

During the last quarter of a century continuous subcutaneous insulin infusion (CSII) with external portable insulin pumps has been increasingly used in selected type 1 diabetic subjects and also in some patients with type 2 diabetes mellitus. The treatment of diabetes mellitus with insulin pumps has become more and more popular and accepted by diabetic patients as well as by medical professionals worldwide. Published trials have shown that, in most patients, mean blood glucose concentration and glycated hemoglobin (HbA1c) percentages are either slightly lower or similar on CSII versus an optimized therapy with multiple daily insulin injections. Hypoglycemic episodes seem to be less frequent and ketoacidoses occur at a comparable rate to that during intensive injection therapy. Moreover, nocturnal glycemic control can be improved with insulin pumps, and automatic basal rate changes help to minimize a prebreakfast blood glucose increase (often called 'the dawn phenomenon'). For many patients, CSII provides greater flexibility in timing of meals with the result of better quality of life and higher treatment satisfaction. However, despite these promising data, and although many patients with diabetes mellitus with well-defined clinical problems are likely to benefit substantially from CSII, either in respect to glycemic control, acute complications or quality of life and treatment satisfaction, we are still far away from reaching'dream diabetes management', the fully automatic closed-loop system. Presently, the most difficult problem concerns not the design of an 'optimal' insulin pump, but rather the development of a system which is able to provide continuous and reliable blood glucose monitoring. Hence, because this problem has not been solved with maximum satisfaction, the development of a feedback-controlled 'artificial pancreas' is one of the main goals in diabetes management in the new millennium.
 ...
PMID:Continuous subcutaneous insulin infusion in patients with diabetes mellitus. 1291 49

Hypoglycemic episodes in patients with diabetes often go unrecognized, and over time, patients may lose the ability to sense hypoglycemia, increasing their risk. Intensive diabetes control is beneficial for patients with diabetes, but it increases their risk of hypoglycemia, underscoring the complexity of diabetes management.
 ...
PMID:Hypoglycemia in diabetes: common, often unrecognized. 1511 75

Regular physical activity plays a key role in the management of children and adolescents with Type 1 diabetes mellitus but it is not considered as a treatment for diabetes. Aim of this study was to investigate time spent exercising, adherence to the programme for a safe exercise and ability of young people with diabetes to take appropriate measures to reduce potential risks. Ninety one Type 1 diabetes mellitus young people (aged from 10 to 18 years, duration of diabetes longer than 6 months) without associated chronic diseases were randomly enrolled in the study. Age, sex, weight, height, BMI, duration of disease, mean HbA1c value over preceding 6 months have been collected. The time weekly spent for physical activity, the type of exercise usually performed, the measures taken to reduce exercise risks have been collected by a structured questionnaire. BMI was 21.6+/-3.05 in the boys and 21.3+/-3.63 in the girls. All patients spent exercising 438+/-221 minutes/week. Boys exercised 71 minutes longer than girls in competitive sports. Children exercising less than 60 minutes weekly showed a mean HbA1c level (8,9+/-05%) higher than that found in children exercising 120-360 minutes (8,3+/-0.4 %; p=0.002) or 360-480 minutes (8,0+/-0.6 %; p< 0.01) weekly. Children attending a competitive sport (at least 360 min per week) had a better glycemic control (HbA1c=7,39+/-0.6 %; p=0.03) than other active peers. Fifty percent of patients reported to monitor blood glucose levels during exercise; 32 % changed insulin dose according to blood glucose levels; 60 % usually added carbohydrate-based foods before (35%), during (15%) or after (10%) exercise. Hypoglycemic episodes (37.7%) were reported more frequently than hyperglycemic ones (p=0.024), but only twelve percent of them were symptomatic and appeared 30 minutes to 2 hours after the end of exercise. These results must encourage health care professionals to review regularly the ability of their patients in managing physical activity and to check their adherence to the program for a safe exercise.
 ...
PMID:Adherence to physical activity in young people with type 1 diabetes. 1579 88


1 2 Next >>